Back to Search Start Over

Feasibility of Veno-Venous Extracorporeal Membrane Oxygenation Using ProtekDuoTM Cannula Ina Patients with COVID-19-Associated Acute Respiratory Distress Syndrome with Severe Right Heart Dysfunction Before Lung Transplantation.

Authors :
Toyoda, T.
Nayak, T.
Arunachalam, A.
Thomae, B.L.
Kandula, V.
Manerikar, A.J.
Jankowski, M.
Kaiho, T.
Yagi, Y.
Cerier, E.
Maganti, K.
Tomic, R.
Budinger, G.
Bharat, A.
Kurihara, C.
Source :
Journal of Heart & Lung Transplantation. 2023 Supplement, Vol. 42, pS423-S424. 2p.
Publication Year :
2023

Abstract

Severe right heart failure (RHF) is a known complication of pulmonary hypertension, which increases mortality before lung transplantation. The safety and feasibility of venovenous (VV)-extracorporeal oxygenation (ECMO) using ProtekDuoTM (CardiacAssist Inc., Pittsburgh, PA) as a bridge to lung transplantation in severe RHF caused have not been well studied. This study aimed to evaluate the safety and feasibility of VV-ECMO using ProtekDuoTM as a bridge to lung transplantation in patients with severe RHF. This study was a prospective review of the institutional lung transplantation database from June 2020 to June 2022. Patients who underwent lung transplantation with VV-ECMO using ProtekDuoTM for COVID-19 associated acute respiratory distress syndrome (ARDS) were prospectively enrolled; and preoperative and postoperative transthoracic echocardiographic (TTE) data were analyzed. RV function and size were evaluated and scored. The Wilcoxon signed-rank test was used to compare pre- and post-operative TTE values. During the study period, 20 patients underwent lung transplantation for COVID-19-associated ARDS with preoperative VV-ECMO using ProtekDuoTM. TTE was assessed at a median of 15 days preoperatively (IQR, 7.75-31) and 155.5 days postoperatively (IQR, 112-210). Pre and post-operative median RVSP was 45.4 mm Hg (IQR, 29.4-49.0) and 30.0 mm Hg (IQR, 28.0-35.0), p=0.02, and the median mitral valve A was 0.70 cm/s (IQR, 0.70-0.80) and 0.55 cm/s (IQR, 0.50-0.70), p=0.03 (Table1). All patients were hemodynamically stable with active rehabilitation and did not require inotropes or inhaled nitric oxide. VV-ECMO with ProtekDuoTM for patients with COVID-19-associated ARDS before lung transplantation can stabilize patients without significant complications and allows active rehabilitation of patients with severe RHF. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10532498
Volume :
42
Database :
Academic Search Index
Journal :
Journal of Heart & Lung Transplantation
Publication Type :
Academic Journal
Accession number :
162850079
Full Text :
https://doi.org/10.1016/j.healun.2023.02.1092